| REVIEW ARTICLE |
|
| Year : 2016 | Volume
: 3
| Issue : 4 | Page : 118-122 |
|
|
Recognition of allergic bronchopulmonary aspergillosis
Xiao-Pei Cao, Min Xie, Xian-Sheng Liu
Department of Respiratory Diseases, Tongji Hospital, Key Lab of Pulmonary Diseases of Health Ministry, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, Hubei Province, China
Correspondence Address:
Prof. Xian-Sheng Liu
Department of Respiratory Diseases, Tongji Hospital, Key Lab of Pulmonary Diseases of Health Ministry, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, Hubei Province
China
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2225-6482.198493
|
|
|
Allergic bronchopulmonary aspergillosis (ABPA) is a complicated inflammatory condition characterized by an allergic response to the fungus Aspergillus colonizing in the bronchus. It occurs most frequently in patients with asthma or cystic fibrosis. Oral corticosteroids are the standard therapy for ABPA. Antifungal drugs can clear the fungi in the airway, reduce the body's antigen load, decrease the body's allergic reaction, and reduce corticosteroid requirement. Total serum IgE should be used as an index for efficacy assessment during treatment and follow-up. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
